Intermittent Fasting Aids Early Diabetes Outcomes More Than Drugs
25 Jun 2024
Clinical Result
TUESDAY, June 25, 2024 -- Intermittent fasting may be a more effective intervention than drugs for people with early diabetes and either obesity or overweight, according to a study published online June 21 in JAMA Network Open.
Lixin Guo, M.D., from the Chinese Academy of Medical Sciences in Beijing, and colleagues evaluated the effect of intermittent fasting (two nonconsecutive fasting days and five days of habitual intake per week and meal replacement diet (5:2 MR) on glycemic control among patients with early type 2 diabetes compared to metformin and empagliflozin for 16 weeks. Analysis included 405 individuals with overweight or obesity randomly assigned to the groups (1:1:1).
The researchers found that from baseline to week 16, participants in the 5:2 MR group showed the greatest reduction in HbA1c (least-squares mean [LSM], −1.9 percent), which was significantly greater than patients receiving metformin (adjusted LSM difference, −0.3 percent) and empagliflozin (adjusted LSM difference, −0.4 percent). The mean weight loss in the 5:2 MR group (LSM, −9.7 kg) was also greater at week 16 than the metformin (LSM, −5.5 kg) and empagliflozin (LSM, −5.8 kg) groups.
"The 5:2 MR approach may serve as an effective initial lifestyle intervention instead of antidiabetic drugs for patients with type 2 diabetes," the authors write.
Abstract/Full Text
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.